Membrane-based plasma collection device for point-of-care diagnosis of HIV

2011 ◽  
Vol 173 (1) ◽  
pp. 37-42 ◽  
Author(s):  
Arman Nabatiyan ◽  
Zaheer A. Parpia ◽  
Robert Elghanian ◽  
David M. Kelso
Keyword(s):  
Point Of Care ◽  
Collection Device ◽  
Plasma Collection

scholarly journals Use of a Dry-Plasma Collection Device to Overcome Problems with Storage and Transportation of Blood Samples for Epidemiology Studies in Developing Countries

2000 ◽  
Vol 7 (6) ◽  
pp. 882-884 ◽  
Author(s):  
Zhannat Z. Nurgalieva ◽  
R. Almuchambetova ◽  
A. Machmudova ◽  
D. Kapsultanova ◽  
Michael S. Osato ◽  
...  
Keyword(s):  
Developing Countries ◽  
Rural Areas ◽  
Relative Sensitivity ◽  
The United States ◽  
Enzyme Linked Immunosorbent Assay ◽  
Plasma Samples ◽  
Serum Samples ◽  
Collection Device ◽  
Epidemiology Studies ◽  
Plasma Collection

ABSTRACT Studies are difficult in areas lacking modern facilities due to the inability to reliably collect, store, and ship samples. Thus, we sought to evaluate the use of a dry plasma collection device for seroepidemiology studies. Plasma was obtained by fingerstick using a commercial dry plasma collection device (Chemcard Plasma Collection Device) and serum (venipuncture) from individuals in Kazakhstan. Plasma samples were air dried for 15 min and then stored desiccated in foil zip-lock pouches at 4 to 6°C and subsequently shipped to the United States by air at ambient temperature. Serum samples remained frozen at −20°C until assayed. Helicobacter pylori status was determined by enzyme-linked immunosorbent assay (HM-CAP EIA) for the dry plasma and the serum samples. The results were concordant in 250 of the 289 cases (86.5%). In 25 cases (8.6%), the dry plasma samples gave indeterminate results and could not be retested because only one sample was collected. Five serum samples were positive, and the corresponding dry plasma samples were negative; one serum sample was negative, and the corresponding plasma sample was positive. The relative sensitivity and specificity of the Chemcard samples to serum were 97.6 and 97.9%, respectively, excluding those with indeterminate results. Repeated freeze-thawing had no adverse effect on the accuracy of the test. We found the dry plasma collection device to provide an accurate and practical alternative to serum when venipuncture may be difficult or inconvenient and sample storage and handling present difficulties, especially for seroepidemiologic studies in rural areas or developing countries and where freeze-thawing may be unavoidable.

Evaluation of a dried plasma collection device for the detection of H. Pylori antibodies

1998 ◽  
Vol 114 ◽  
pp. A90
Author(s):  
E.H. Cheng ◽  
K. Ashraf ◽  
M. Roeske ◽  
F. Rubenbauer ◽  
R. Shaw ◽  
...  
Keyword(s):  
Collection Device ◽  
H Pylori ◽  
Plasma Collection

Use of a dry plasma collection device for H. pylori IgG antibodies in Kazakhstan

2000 ◽  
Vol 95 (9) ◽  
pp. 2469-2469
Author(s):  
E. White ◽  
Z.Z. Nurgalieva ◽  
M.S. Osato ◽  
U. Sherwani ◽  
J. Peacock ◽  
...  
Keyword(s):  
Igg Antibodies ◽  
Collection Device ◽  
H Pylori ◽  
Plasma Collection

scholarly journals Use of Oral Fluid in a Rapid Syphilis Test Assay

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S107-S108 ◽  
Author(s):  
Chelsea Shannon ◽  
Claire Bristow ◽  
Sasha Herbst De Cortina ◽  
Jennifer Chang ◽  
Jeffrey Klausner
Keyword(s):  
Whole Blood ◽  
Oral Fluid ◽  
Point Of Care ◽  
Fluid Collection ◽  
Treponema Pallidum ◽  
Rapid Test ◽  
High Sensitivity ◽  
The United States ◽  
Collection Device ◽  
Positive Results

Abstract Background From 2014 to 2015, the syphilis rate in the United States increased by 19%, reaching its highest rate since 1994. Currently, point-of-care syphilis assays use fingerstick or venipuncture whole blood to identify Treponema pallidum (TP) antibodies by qualitative immunoassay. However, patients and providers prefer oral fluid testing to whole blood testing. In this study, we aimed to determine whether a rapid syphilis test intended for use on whole blood could be used to detect TP antibodies in oral fluid. Methods Oral fluid was collected from 72 participants using the Super•SAL™ Oral Fluid Collection Device (Oasis Diagnostics®, Vancouver, WA). The device uses an absorbent cylindrical pad to collect and filter ~1 mlml of oral fluid. Oral fluid filtrate was tested using the SD Bioline Syphilis 3.0 rapid test (Alere Diagnostics, MA) following manufacturer directions for whole blood. TP particle agglutination (TPPA) and rapid plasma reagin (RPR) results derived from participants’ medical records were used as reference values. We used three different definitions as comparators: 1: TPPA reactive; 2: TPPA and RPR reactive and 3: TPPA reactive and RPR titer >1:4. Those with non-reactive TPPA and RPR results were considered seronegative. We calculated the sensitivity and specificity for definition 1 and sensitivity for definitions 2 and 3. We used the exact binomial method to determine 95% confidence intervals (CI). Results With definitions 1, 2, and 3, respectively, sensitivity was 83.3% (CI: 67.2, 93.6), 86.4% (CI: 65.1, 97.1), and 100% (CI: 71.5, 100). Specificity was 47.2% (CI: 36.5, 75.5). Conclusion The high sensitivity of the SD Bioline Syphilis 3.0 test using oral fluid suggests a strong potential for the development of accurate rapid oral syphilis tests. Sensitivity increased with higher RPR titer. False positive results may be due to the presence of non-venereal treponemal antibodies in oral fluid. Further research and development are needed to optimize specificity. Disclosures All authors: No reported disclosures.

scholarly journals Rapidly Establishing a Hospital-Based Convalescent Plasma Collection Center With the Alyx Apheresis Collection Device

2021 ◽  
Vol 8 ◽  
pp. 237428952098723
Author(s):  
Tovah Klein ◽  
Rita Elue ◽  
Sachie Ikegami ◽  
Christopher Mikkelson ◽  
Gregory Wright ◽  
...  
Keyword(s):  
Vital Signs ◽  
Reaction Rates ◽  
Nasopharyngeal Swab ◽  
Infiltration Rates ◽  
Collection Device ◽  
Target Yield ◽  
Screening Questions ◽  
Access Program ◽  
Plasma Collection ◽  
Collection Program

The effort to collect convalescent plasma from individuals who recovered from COVID-19 began in earnest during the spring of 2020. Either whole blood or apheresis donations were obtained, the latter yielding higher numbers of units per donor per collection and more frequent collections. The NorthShore University HealthSystem blood donor center purchased 2 Alyx (Fresenius Kabi) apheresis plasma collection devices and quickly implemented them in order to collect COVID-19 convalescent plasma. Apheresis-experienced and inexperienced phlebotomists operated the instruments. Donors were collected >14 days from symptom resolution and all donors were negative by SARS-CoV-2 nasopharyngeal swab. Both internal metrics of performance as well as a post donation survey were used to evaluate the feasibility implementing this collection program. During the first 100 days of the collection program, 650 plasma units were collected. In particular, during the first week of the program, 38 units were collected and distributed to hospitals under the emergency investigational new drug and expanded access program. Fifty-one donors (15%) were deferred due to vital signs out of range or donor screening questions. Thirty-one donors (10%) were deferred due to positive nasopharyngeal swab. Lower than target yield occurred in 16.6% of collections due to donor reactions or flow errors. Donors rated the overall program lower, but not the staff, when they reported symptoms related to collection. In conclusion, a hospital-based apheresis convalescent plasma collection program can be rapidly implemented. Donor reaction rates and vein infiltration rates should be carefully monitored for each phlebotomist.

scholarly journals Performance of a FRET-Based Point-of-Care Immunoassay for the Quantitation of Fecal Calprotectin

2021 ◽  
Author(s):  
Manisha Yadav ◽  
Michael Skinner ◽  
Rukmini Reddy ◽  
Matthew Wong ◽  
Kevin Chon ◽  
...  
Keyword(s):  
Point Of Care ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Fecal Calprotectin ◽  
Analytical Performance ◽  
Quantitative Detection ◽  
Time Resolved ◽  
Collection Device ◽  
Sensitivity Specificity ◽  
A Current

<p>A fast (~5 min), time-resolved fluorescence resonance energy transfer based immunoassay (Procise FCP<a>™</a>) was developed for the point-of-care quantitative detection of fecal calprotectin (FCP) using 15 mg of fecal specimen eluted in collection fluid from the Procise Stool Collection Device™. Studies were performed to characterize analytical performance of the Procise FCP assay on the ProciseDx™ analyzer.</p><p><br></p> <p>The Procise FCP assay showed good analytical performance with respect to sensitivity, specificity, linearity, and precision suitable for routine clinical use in a point-of-care setting as well as excellent analytical agreement with a current commercial FCP measurement method.</p><p><br></p> <p>Results indicate that the Procise FCP assay is sensitive, specific, and precise yielding results in less than 5 minutes. This indicates the Procise FCP assay is useful for obtaining fast and accurate FCP quantitation, thus avoiding delays inherent to current methods and enabling immediate clinical assessment to be made during a single patient visit.</p>

scholarly journals Performance of a FRET-Based Point-of-Care Immunoassay for the Quantitation of Fecal Calprotectin

2021 ◽  
Author(s):  
Manisha Yadav ◽  
Michael Skinner ◽  
Rukmini Reddy ◽  
Matthew Wong ◽  
Kevin Chon ◽  
...  
Keyword(s):  
Point Of Care ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Fecal Calprotectin ◽  
Analytical Performance ◽  
Quantitative Detection ◽  
Time Resolved ◽  
Collection Device ◽  
Sensitivity Specificity ◽  
A Current

<p>A fast (~5 min), time-resolved fluorescence resonance energy transfer based immunoassay (Procise FCP<a>™</a>) was developed for the point-of-care quantitative detection of fecal calprotectin (FCP) using 15 mg of fecal specimen eluted in collection fluid from the Procise Stool Collection Device™. Studies were performed to characterize analytical performance of the Procise FCP assay on the ProciseDx™ analyzer.</p><p><br></p> <p>The Procise FCP assay showed good analytical performance with respect to sensitivity, specificity, linearity, and precision suitable for routine clinical use in a point-of-care setting as well as excellent analytical agreement with a current commercial FCP measurement method.</p><p><br></p> <p>Results indicate that the Procise FCP assay is sensitive, specific, and precise yielding results in less than 5 minutes. This indicates the Procise FCP assay is useful for obtaining fast and accurate FCP quantitation, thus avoiding delays inherent to current methods and enabling immediate clinical assessment to be made during a single patient visit.</p>

“Aspirin - resistance”? A few critical considerations on definition, terminology, diagnosis, clinical value, natural course of atherosclerotic disease, and therapeutic consequences

VASA ◽  
2011 ◽  
Vol 40 (6) ◽  
pp. 429-438 ◽  
Author(s):  
Berent ◽  
Sinzinger
Keyword(s):  
Platelet Function ◽  
Point Of Care ◽  
Aspirin Resistance ◽  
Point Of View ◽  
Evidence Based ◽  
Platelet Function Tests ◽  
Clinical Value ◽  
Vascular Events ◽  
Therapeutic Consequences ◽  
Function Tests

Based upon various platelet function tests and the fact that patients experience vascular events despite taking acetylsalicylic acid (ASA or aspirin), it has been suggested that patients may become resistant to the action of this pharmacological compound. However, the term “aspirin resistance” was created almost two decades ago but is still not defined. Platelet function tests are not standardized, providing conflicting information and cut-off values are arbitrarily set. Intertest comparison reveals low agreement. Even point of care tests have been introduced before appropriate validation. Inflammation may activate platelets, co-medication(s) may interfere significantly with aspirin action on platelets. Platelet function and Cox-inhibition are only some of the effects of aspirin on haemostatic regulation. One single test is not reliable to identify an altered response. Therefore, it may be more appropriate to speak about “treatment failure” to aspirin therapy than using the term “aspirin resistance”. There is no evidence based justification from either the laboratory or the clinical point of view for platelet function testing in patients taking aspirin as well as from an economic standpoint. Until evidence based data from controlled studies will be available the term “aspirin resistance” should not be further used. A more robust monitoring of factors resulting in cardiovascular events such as inflammation is recommended.

Sign in / Sign up

Export Citation Format

Share Document